Meyer Handelman Co. trimmed its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 7.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,407 shares of the medical instruments supplier’s stock after selling 2,361 shares during the quarter. Meyer Handelman Co.’s holdings in Becton Dickinson and were worth $7,414,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in the business. Acropolis Investment Management LLC bought a new stake in shares of Becton Dickinson and in the 3rd quarter worth approximately $101,000. Almanack Investment Partners LLC. bought a new stake in shares of Becton Dickinson and in the 2nd quarter worth approximately $105,000. Truvestments Capital LLC bought a new stake in shares of Becton Dickinson and in the 3rd quarter worth approximately $105,000. Bartlett & Co. LLC raised its holdings in shares of Becton Dickinson and by 2,900.0% in the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 435 shares in the last quarter. Finally, Bridgeworth LLC bought a new stake in shares of Becton Dickinson and in the 2nd quarter worth approximately $131,000. Institutional investors own 92.60% of the company’s stock.
In related news, Director Timothy M. Ring sold 42,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the transaction, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James C. Lim sold 5,189 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the transaction, the executive vice president now directly owns 13,318 shares in the company, valued at $3,227,750.48. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.
A number of research firms recently commented on BDX. KeyCorp boosted their target price on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a report on Thursday. Barclays set a $260.00 target price on shares of Becton Dickinson and and gave the stock a “hold” rating in a research report on Thursday. Wells Fargo & Co dropped their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday. Piper Jaffray Companies dropped their target price on shares of Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 4th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $254.07.
Becton Dickinson and stock opened at $243.26 on Friday. The company has a market capitalization of $63.38 billion, a PE ratio of 22.09, a PEG ratio of 1.46 and a beta of 1.19. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a fifty-two week low of $209.91 and a fifty-two week high of $265.87.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the previous year, the firm posted $2.40 earnings per share. The firm’s revenue was up 39.0% on a year-over-year basis. On average, equities research analysts predict that Becton Dickinson and Co will post 12.2 earnings per share for the current fiscal year.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.